デフォルト表紙
市場調査レポート
商品コード
1714527

ホルモン補充療法市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、投与経路別、疾患タイプ別、地域別、競合別、2020-2030F

Hormone Replacement Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Route of Administration, By Disease Type, By Region and Competition, 2020-2030F


出版日
ページ情報
英文 183 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

ホルモン補充療法市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、投与経路別、疾患タイプ別、地域別、競合別、2020-2030F
出版日: 2025年04月25日
発行: TechSci Research
ページ情報: 英文 183 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ホルモン補充療法(HRT)の世界市場は、2024年に220億5,000万米ドルと評価され、2030年には320億9,000万米ドルに達し、CAGR 6.43%で成長すると予測されています。

この市場は、人口動態の変化と更年期に関連する健康上の懸念をめぐる意識の高まりによって力強い成長を遂げています。世界人口の高齢化に伴い、更年期を経験する女性が増え、HRT製品に対する需要の急増につながっています。更年期障害は加齢に伴う自然な現象であるが、それに伴う症状-ほてり、寝汗、気分の落ち込みなど-は、HRTによって効果的に緩和されるため、人気が高まっています。HRTの利点と生活の質を高める役割に対する認識が、その採用をさらに拡大しています。加えて、経皮パッチ、ゲル、スプレーなどのHRT送達方法における技術革新は、従来の経口薬に代わる、より安全で非侵襲的な選択肢を提供し、支持を集めています。さらに、体内で自然に生成されるホルモンを反映したバイオアイデンティカル・ホルモンの開発は、より安全で個別化された治療オプションを提供することにより、HRTの魅力を高めています。

市場概要
予測期間 2026-2030
市場規模:2024年 220億5,000万米ドル
市場規模:2030年 320億9,000万米ドル
CAGR:2025年~2030年 6.43%
急成長セグメント 甲状腺機能低下症
最大市場 北米

市場促進要因

老人人口の増加

主な市場課題

安全性への懸念と副作用

主な市場動向

バイオアイデンティカルホルモンへのシフト:

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のホルモン補充療法市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別(エストロゲンおよびプロゲステロン補充療法、HGH補充療法、甲状腺ホルモン補充療法、テストステロン補充療法、副甲状腺ホルモン補充療法)
    • 投与経路別(経口、非経口、経皮、その他)
    • 疾患の種類別(更年期障害、甲状腺機能低下症、男性性腺機能低下症、成長ホルモン欠乏症、副甲状腺機能低下症)
    • 企業別(2024)
    • 地域別
  • 市場マップ

第6章 北米のホルモン補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米:国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のホルモン補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州:国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のホルモン補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のホルモン補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのホルモン補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • Merck KGaA
  • Bayer AG
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 15746

The Global Hormone Replacement Therapy (HRT) Market was valued at USD 22.05 billion in 2024 and is projected to reach USD 32.09 billion by 2030, growing at a CAGR of 6.43%. This market is witnessing robust growth, driven by demographic changes and heightened awareness surrounding menopause-related health concerns. As the global population ages, more women are experiencing menopause, leading to a surge in demand for HRT products. While menopause is a natural part of aging, its associated symptoms-such as hot flashes, night sweats, and mood swings-are alleviated effectively by HRT, which is becoming increasingly popular. Awareness of its benefits and its role in enhancing quality of life is further expanding its adoption. In addition, technological innovations in HRT delivery methods, such as transdermal patches, gels, and sprays, are gaining traction, offering safer, non-invasive alternatives to traditional oral medications. Moreover, the development of bioidentical hormones, which mirror the body's naturally produced hormones, enhances the appeal of HRT by offering safer and more personalized treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 22.05 Billion
Market Size 2030USD 32.09 Billion
CAGR 2025-20306.43%
Fastest Growing SegmentHypothyroidism
Largest MarketNorth America

Key Market Drivers

Growth in Geriatric Population:

The aging population is a major driver for the global HRT market, as hormonal imbalances, particularly menopause, are more prevalent among older adults. By 2025, over 1 billion women globally will be experiencing menopause, with many suffering from symptoms such as hot flushes, vaginal dryness, night sweats, and weight gain. These issues are often addressed through HRT, fueling market growth. Additionally, other hormonal disorders like hypothyroidism, andropause, and adrenal insufficiency, which are more common with aging, further contribute to the demand for HRT.

Key Market Challenges

Safety Concerns and Side Effects:

Despite its popularity, HRT faces significant challenges, particularly regarding safety concerns. Prolonged use of hormone therapies has been linked to increased risks of conditions such as breast cancer, blood clots, and cardiovascular diseases. These risks, especially in women undergoing menopause treatment, have sparked debates within the medical community about the long-term safety of HRT. Furthermore, patients report a range of side effects, from mood swings and headaches to more severe issues like weight gain and nausea. Such concerns impact patient satisfaction and the broader adoption of HRT, with regulatory restrictions complicating market growth. The uncertainty surrounding long-term safety and the variety of available formulations further complicate healthcare providers' ability to recommend optimal treatments, limiting the market's expansion.

Key Market Trends

Shift Toward Bioidentical Hormones:

A growing trend within the HRT market is the shift towards bioidentical hormones. These hormones are chemically identical to those naturally produced by the body, and they are increasingly favored for their perceived safety and efficacy. Bioidentical hormones are promoted as offering a more natural alternative to synthetic hormone therapies, leading to their rising popularity. Tailored to individual needs based on hormone levels, bioidentical hormone therapy (BHT) provides a personalized solution compared to traditional hormone treatments. This trend reflects a broader shift toward personalized healthcare and is expected to further drive the market.

Key Market Players

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • Merck KGaA
  • Bayer AG
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope

This report segments the Global Hormone Replacement Therapy Market as follows:

By Product:

  • Estrogen & Progesterone Replacement Therapy
  • HGH Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Replacement Therapy
  • Parathyroid Hormone Replacement

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal
  • Others

By Disease Type:

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Hypoparathyroidism

By Region:

  • North America: United States, Canada, Mexico
  • Europe: France, United Kingdom, Italy, Germany, Spain
  • Asia-Pacific: China, India, Japan, Australia, South Korea
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of the leading players in the global HRT market, focusing on their market share, strategies, and innovations. Customization options for this report are also available, allowing companies to access further details about additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hormone Replacement Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Estrogen & Progesterone Replacement Therapy, HGH Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, Parathyroid Hormone Replacement)
    • 5.2.2. By Route of Administration (Oral, Parenteral, Transdermal, Others)
    • 5.2.3. By Disease Type (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Hypoparathyroidism)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Hormone Replacement Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Route of Administration
    • 6.2.3. By Disease Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hormone Replacement Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Disease Type
    • 6.3.2. Mexico Hormone Replacement Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Disease Type
    • 6.3.3. Canada Hormone Replacement Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Disease Type

7. Europe Hormone Replacement Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Route of Administration
    • 7.2.3. By Disease Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Hormone Replacement Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Disease Type
    • 7.3.2. Germany Hormone Replacement Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Disease Type
    • 7.3.3. United Kingdom Hormone Replacement Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Disease Type
    • 7.3.4. Italy Hormone Replacement Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Disease Type
    • 7.3.5. Spain Hormone Replacement Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Disease Type

8. Asia-Pacific Hormone Replacement Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Route of Administration
    • 8.2.3. By Disease Type
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hormone Replacement Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Disease Type
    • 8.3.2. India Hormone Replacement Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Disease Type
    • 8.3.3. South Korea Hormone Replacement Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Disease Type
    • 8.3.4. Japan Hormone Replacement Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Disease Type
    • 8.3.5. Australia Hormone Replacement Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Disease Type

9. South America Hormone Replacement Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Route of Administration
    • 9.2.3. By Disease Type
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hormone Replacement Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Disease Type
    • 9.3.2. Argentina Hormone Replacement Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Disease Type
    • 9.3.3. Colombia Hormone Replacement Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Disease Type

10. Middle East and Africa Hormone Replacement Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Route of Administration
    • 10.2.3. By Disease Type
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Hormone Replacement Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Disease Type
    • 10.3.2. Saudi Arabia Hormone Replacement Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Disease Type
    • 10.3.3. UAE Hormone Replacement Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Disease Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Novartis AG
  • 14.4. Merck KGaA
  • 14.5. Bayer AG
  • 14.6. Eli Lilly and Company
  • 14.7. Novo Nordisk A/S
  • 14.8. F. Hoffmann-La Roche Ltd.
  • 14.9. Amgen Inc.
  • 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer